476 related articles for article (PubMed ID: 23358903)
21. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
22. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
24. Triple negative breast cancer: unmet medical needs.
Pal SK; Childs BH; Pegram M
Breast Cancer Res Treat; 2011 Feb; 125(3):627-36. PubMed ID: 21161370
[TBL] [Abstract][Full Text] [Related]
25. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
27. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Kelly CM; Buzdar AU
Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative breast cancer--current status and future directions.
Gluz O; Liedtke C; Gottschalk N; Pusztai L; Nitz U; Harbeck N
Ann Oncol; 2009 Dec; 20(12):1913-27. PubMed ID: 19901010
[TBL] [Abstract][Full Text] [Related]
29. Triple-negative breast cancer: role of specific chemotherapy agents.
Isakoff SJ
Cancer J; 2010; 16(1):53-61. PubMed ID: 20164691
[TBL] [Abstract][Full Text] [Related]
30. Targeting basal-like breast cancers.
Dey N; Smith BR; Leyland-Jones B
Curr Drug Targets; 2012 Nov; 13(12):1510-24. PubMed ID: 22974394
[TBL] [Abstract][Full Text] [Related]
31. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
32. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.
Penault-Llorca F; Viale G
Ann Oncol; 2012 Aug; 23 Suppl 6():vi19-22. PubMed ID: 23012297
[TBL] [Abstract][Full Text] [Related]
33. Updates in the treatment of basal/triple-negative breast cancer.
Shastry M; Yardley DA
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targets in triple negative breast cancer.
O'Toole SA; Beith JM; Millar EK; West R; McLean A; Cazet A; Swarbrick A; Oakes SR
J Clin Pathol; 2013 Jun; 66(6):530-42. PubMed ID: 23436929
[TBL] [Abstract][Full Text] [Related]
35. [PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer].
Kozioł M; Püsküllüoglu M; Zygulska A
Przegl Lek; 2012; 69(6):265-70. PubMed ID: 23094440
[TBL] [Abstract][Full Text] [Related]
36. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
[TBL] [Abstract][Full Text] [Related]
37. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
Liu N; Wang X; Sheng X
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
39. [Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer].
Kan N; Kuwata K; Mise K; Kodama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1259-64. PubMed ID: 20647706
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
